Kura Oncology (NASDAQ:KURA) Downgraded to “Sell” at StockNews.com

StockNews.com downgraded shares of Kura Oncology (NASDAQ:KURAFree Report) from a hold rating to a sell rating in a research note released on Monday morning.

A number of other research firms have also recently commented on KURA. HC Wainwright reaffirmed a buy rating and issued a $32.00 target price on shares of Kura Oncology in a research report on Friday, December 8th. Mizuho began coverage on shares of Kura Oncology in a research note on Friday, December 22nd. They set a buy rating and a $26.00 price target on the stock. JMP Securities boosted their price target on shares of Kura Oncology from $22.00 to $32.00 and gave the stock a market outperform rating in a research note on Wednesday, January 31st. Finally, Wedbush cut their price target on shares of Kura Oncology from $40.00 to $37.00 and set an outperform rating on the stock in a research note on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $28.28.

Read Our Latest Analysis on KURA

Kura Oncology Trading Up 2.2 %

NASDAQ KURA opened at $20.40 on Monday. The firm’s 50-day moving average is $15.41 and its two-hundred day moving average is $11.56. Kura Oncology has a 12 month low of $7.41 and a 12 month high of $22.92. The company has a debt-to-equity ratio of 0.02, a current ratio of 16.71 and a quick ratio of 16.71. The stock has a market capitalization of $1.52 billion, a P/E ratio of -10.10 and a beta of 0.85.

Insider Buying and Selling

In related news, COO Kathleen Ford sold 1,496 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $17.80, for a total transaction of $26,628.80. Following the sale, the chief operating officer now directly owns 21,602 shares in the company, valued at $384,515.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Kura Oncology news, COO Kathleen Ford sold 1,496 shares of the stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $17.80, for a total value of $26,628.80. Following the transaction, the chief operating officer now directly owns 21,602 shares in the company, valued at $384,515.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Troy Edward Wilson sold 91,052 shares of the stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $20.23, for a total transaction of $1,841,981.96. Following the completion of the transaction, the chief executive officer now owns 559 shares in the company, valued at $11,308.57. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 96,919 shares of company stock worth $1,946,415. Company insiders own 5.60% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds have recently added to or reduced their stakes in KURA. Prosight Management LP acquired a new stake in shares of Kura Oncology in the second quarter valued at approximately $14,213,000. State Street Corp boosted its holdings in shares of Kura Oncology by 44.1% in the third quarter. State Street Corp now owns 4,368,763 shares of the company’s stock valued at $59,677,000 after acquiring an additional 1,337,149 shares during the period. Deerfield Management Company L.P. Series C boosted its holdings in shares of Kura Oncology by 35.1% in the third quarter. Deerfield Management Company L.P. Series C now owns 4,374,044 shares of the company’s stock valued at $39,891,000 after acquiring an additional 1,136,044 shares during the period. BlackRock Inc. boosted its holdings in shares of Kura Oncology by 14.7% in the second quarter. BlackRock Inc. now owns 6,157,402 shares of the company’s stock valued at $65,145,000 after acquiring an additional 788,095 shares during the period. Finally, Affinity Asset Advisors LLC boosted its holdings in shares of Kura Oncology by 154.8% in the second quarter. Affinity Asset Advisors LLC now owns 910,317 shares of the company’s stock valued at $9,631,000 after acquiring an additional 553,030 shares during the period.

About Kura Oncology

(Get Free Report)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications.

See Also

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.